The Web TechnoInternet, crypto and technology announcements

Press Release · Biointron

RushDATA™ Enables Wet-Lab Validation of AI-Designed Antibodies Generated by Molence Bio's Mol-1

Distributed by The Web Techno · Originally issued via PR Newswire

CAMBRIDGE, Mass., Nov. 13, 2026 — Biointron Biological USA Inc. ("Biointron") is pleased to have supported Molence Bio's Mol-1 project. Mol-1 demonstrates performance comparable to the leading closed-source model IsoDDE in antibody-antigen structure prediction and is capable of designing functional nanobodies from scratch. To experimentally evaluate these AI-designed candidates, Biointron conducted developability assays using RushDATA™, its wet-lab validation service for AI-designed antibodies.

Biointron's RushDATA™ Enables Wet-Lab Validation of AI-Designed Antibodies Generated by Molence Bio’s Mol-1

The results: 23 out of 30 AI-designed candidates met at least three of the four developability criteria, demonstrating promising developability profiles.

Wet-Lab Validation with RushDATA™

AI-designed antibodies require experimental validation to demonstrate their potential as viable drug candidates. Biointron ran the developability panel on Molence Bio's VHH-Fc candidates, measuring properties that predict manufacturability and safety, including hydrophobicity, thermal stability, self-interaction, and non-specific binding.

Each assay was benchmarked against Biointron reference antibodies, including infliximab, bevacizumab, bococizumab, gantenerumab and trastuzumab, so the designs could be compared directly with approved and clinical-stage antibodies.

Bridging AI Design and Wet-Lab Validation

RushDATA™ is Biointron's wet-lab validation service for AI-designed antibodies, combining a capacity of 10,000+ antibodies per day with sequence-to-data turnaround in as little as 2 days with cell-free expression or 3 days with CHO expression.

The service offers multi-point binding affinity measurements by BLI or SPR, alongside developability profiling using DSF, PSR-BVP, and AC-SINS. Results are delivered as structured, model-ready datasets with API access, allowing experimental findings to feed directly into the next round of AI-guided design.

Why This Matters for AI-Driven Antibody Discovery

AI can now generate antibody binders at scale. The next challenge is proving which designs work in the lab and behave like drugs. Mol-1 shows what happens when a strong open model meets high-quality experimental data, and Biointron is proud to provide that data.

Biointron congratulates Molence Bio on the launch of Mol-1 and looks forward to supporting the researchers who build on it.

Contact

Media contact: Mia Deng
Biointron
+1 (732) 790-8340
[email protected]
20 University Road, Suite 500, Cambridge, MA 02138 

SOURCE Biointron

About Biointron

Founded in 2012, Biointron is a global antibody discovery CRO trusted by 3,000+ organizations in 20+ countries and regions, including top 20 pharma companies. Our RushDATA™ platform generates wet-lab data for AI-designed antibodies at scale, expressing 10,000+ antibodies a day and delivering binding and developability results in as little as 2 days, ready to feed your models via API. We also offer end-to-end antibody services from discovery to large-scale production. Several partner projects using our CHOK1BN cell line have entered multicenter international clinical trials successfully.

Learn more about RushDATA™: https://www.biointron.com/antibody-production/rushdata.html

About Molence Bio

Molence Bio is an AI-native biotech built on their own biomolecular foundation models. Their biologists, chemists, and AI researchers work side by side to advance these models and apply them to drug discovery: unlocking targets long considered undruggable, designing better molecules, and building a pipeline of therapies for unmet medical needs.

Access the model weights: https://github.com/molence/Mol-1